Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of ... Read More
-
Myasthenia Gravis Drugs
... at a CAGR of 6.6% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Schizophrenia Therapeutics
... CAGR of 4.2% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$7.7 Billion by the end of ... Read More
-
Glioblastoma Multiforme Treatment (GBM)
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the ... Read More
-
Periodontal Therapeutics
... CAGR of 8.6% over the analysis period 2024-2030. Systemic Antibiotics, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$623.3 Million by the end of the analysis ... Read More
-
Plasma Protein Therapeutics
... at a CAGR of 4.8% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.3 Billion by the end of the ... Read More
-
Respiratory Syncytial Virus (RSV) Therapeutics
... Billion by 2030, growing at a CAGR of 29.2% over the analysis period 2024-2030. Prophylaxis Drugs, one of the segments analyzed in the report, is expected to record a 28.4% CAGR and reach US$7.6 Billion ... Read More
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & marketing, Drug Safety), End User (Pharma, Medical Device), & Region - Global Forecast to 2029
... grow as a result of the heterogenity & complexity of big data in life sciences, surging demand for technologically advanced analytical solutions for various applications across the industry, such as, research & development, commercialization (market ... Read More
-
Endometriosis Drugs
... CAGR of 3.0% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end of the analysis ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Biosimulation Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. HCS Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Women's Health Therapeutics
... at a CAGR of 12.9% over the analysis period 2024-2030. Postmenopausal Osteoporosis Application, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$18.1 Billion by the end ... Read More
-
Epilepsy Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
... of the main reasons driving the market expansion are the increased prevalence of epilepsy globally, notable developments in drug discovery and innovation, greater knowledge of epilepsy and available treatments, rising healthcare costs, and better access ... Read More
-
Pediatric Epilepsy Therapeutics
... at a CAGR of 3.3% over the analysis period 2024-2030. Third Generation Therapeutics, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$7.0 Billion by the end ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Hypercalcemia Treatment
... CAGR of 9.3% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$28.0 Billion by the end of the analysis period. ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
-
Diabetic Macular Edema Treatment
... 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Microbiome Therapeutics
... CAGR of 56.8% over the analysis period 2024-2030. C. Difficile Infection Indication, one of the segments analyzed in the report, is expected to record a 53.0% CAGR and reach US$7.3 Billion by the end of ... Read More
-
MRSA Drugs
... CAGR of 4.5% over the analysis period 2024-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end of the ... Read More
Research Assistance
